Category: Intl’ Pharmaceuticals

Intl' Pharmaceuticals


Positive Data for Tagrisso in Patients with EGFR-mutated NSCLC

A Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) plus chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-free survival for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and brain metastases at baseline.